(Q44328208)

2 December 2017

1 reference

title

Clinical trials with rofecoxib: analysis of the information from the gender perspective (English)

1 reference

2 December 2017

author name string

Susana Cascales Pérez

series ordinal

1

1 reference

2 December 2017

M Teresa Ruiz Cantero

series ordinal

2

1 reference

2 December 2017

María Angeles Pardo

series ordinal

3

1 reference

2 December 2017

language of work or name

Spanish

0 references

publication date

1 February 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

120

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

207-212

1 reference

A two way view of gender bias in medicine

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Women in clinical drug trials. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Don't Test, Do Sell: Legal Implications of Inclusion and Exclusion of Women in Clinical Drug Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Historical background of changes in FDA policy on the study and evaluation of drugs in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Women in clinical trials of new drugs. A change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Women in clinical trials--a portfolio for success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Risk of cardiovascular events associated with selective COX-2 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Safety of celecoxib and rofecoxib: a critical overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Gender bias in clinical trials: do double standards still apply?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

Inclusion of women in clinical trials--policies for population subgroups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2803%2973653-7

RETRACTED: Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery

7 January 2021

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1097/00000539-200011000-00032

Identifiers

DOI

10.1016/S0025-7753(03)73653-7

1 reference

2 December 2017

1 reference